AGCO Unveils Next Generation of Axial Combines
AGCO (NYSE: AGCO), a worldwide manufacturer and distributor of agricultural equipment, today unveiled IDEAL, its new top range combine harvester, in Breganze, Italy. “The IDEAL combine is the result of many years of R&D, countless engineering hours, committed teamwork, and leading industry expertise,” said Martin Richenhagen, AGCO Chairman, President and CEO. “It is yet another result of AGCO’s tireless efforts to deliver the most innovative solutions to farmers feeding the world.”
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170905005414/en/
Fendt IDEAL. Recolour your Harvest. (Photo: Business Wire)
The development of the IDEAL combine is also a significant step to continuously strengthen AGCO’s global harvesting offering and to solidify AGCO’s position as the leading full line manufacturer of agricultural solutions.
The new generation of combines is the result of a global “Voice of Customer” study. The findings showed that there is a need for an entirely new combine platform, prompting AGCO’s R&D team to start from a “blank sheet of paper.”
A global team from different AGCO sites developed the features customers had pointed out in the study. “IDEAL is part of AGCO’s global platform strategy that supports synergies across different regions, saves cost, and optimizes supply chain management. Like AGCO’s Global Series tractors, this combine platform expresses our commitment to brand-new designs, and to practical solutions that empower farmers across the world to be more productive and to feed a growing world population,” said Eric Hansotia, Senior Vice President, Global Crop Cycle & Fuse Connected Services.
Close to 50 combine prototypes were built and tested in the lab, on the field and around the globe in varying environments to develop a unique combine that is able to be used for all crops and operate in all conditions, in all parts of the world.
“Our customers harvest in many different conditions, and each farm has a unique set of requirements for their operation,” continued Hansotia. “The IDEAL combine aims at exceeding our customers’ needs and expectations. It is the most innovative combine we have ever produced and an investment in the future of harvesting. IDEAL will change the way harvesting is done today.”
At the heart of the IDEAL combine is an efficient processing system which outperforms on grain and straw quality, grain handling, power efficiency, and capacity in a wide variety of conditions.
The IDEAL combine features the latest patented innovations from AGCO’s Fuse Connected Services division, is fully connected, offers an automated combine adjustment system, and Real Time Crop Flow visualization.
IDEAL stands for ease of use and optimizing complex harvesting operations by providing the efficiency, visibility and the comfort farmers need on the field.
IDEAL is the first high capacity combine of its kind with such a narrow body and unique for its impressive design. IDEAL is designed for convenient road transportation.
IDEAL will be available in three of AGCO’s core brands: Challenger, Fendt and Massey Ferguson and will debut at Agritechnica in November 2017.
The new combine will be launched into different markets in 2018. IDEAL will be offered in 3 different models, 7, 8 and 9, will be available with tires or tracks, and also in ParaLevel version.
For more information about the product, please see the Fendt press release and the Massey Ferguson press release.
Fendt: http://www.fendt.com/int/news-center.html
Massey Ferguson: http://int.masseyferguson.com/press-centre.aspx
About AGCO
AGCO (NYSE: AGCO) is a global leader in the design, manufacture and distribution of agricultural solutions and supports more productive farming through its full line of equipment and related services. AGCO products are sold through five core brands, Challenger®, Fendt®, GSI®, Massey Ferguson® and Valtra®, supported by Fuse® precision technologies and farm optimization services, and are distributed globally through a combination of over 3,000 independent dealers and distributors in more than 150 countries. Founded in 1990, AGCO is headquartered in Duluth, GA, USA. In 2016, AGCO had net sales of $7.4 billion. For more information, visit http://www.AGCOcorp.com. For company news, information and events, please follow us on Twitter: @AGCOCorp. For financial news on Twitter, please follow the hashtag #AGCOIR.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170905005414/en/
Contact information
AGCO
Sepp Nuscheler, +49834277343
Josef.Nuscheler@agcocorp.com
or
Paul
Lay, +442476851209
Paul.Lay@agcocorp.com
or
Abby
Burton, +17708136167
Abby.Burton@agcocorp.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CCM Biosciences Announces Presentation of Data on its First-In-Class AML Drug Program at ASCO 202520.5.2025 23:30:00 EEST | Press release
CCM Biosciences, a diversified pharmaceutical discovery and development company, today announced the upcoming presentation of its next-generation FLT3 inhibitor drug program for acute myeloid leukemia (AML) at the 2025 Annual Conference of the American Society of Clinical Oncology (ASCO), taking place May 30 to June 3 in Chicago. Acute Myeloid Leukemia (AML) is the most severe form of leukemia with few treatment options, and a malignancy frequently driven by mutations in the FMS-like tyrosine kinase 3 (FLT3) gene. The FLT3 internal tandem duplication (ITD) and tyrosine kinase domain (TKD) mutations, particularly D835 and F691, appear in approximately 30% of AML patients, often leading to poor prognosis and resistance to existing therapies. Gilteritinib (Xospata®; Astellas Pharma, peak annual sales projection: $1.5 billion) and Quizartinib (Vanflyta®; Daiichi Sankyo) are two FDA-approved FLT3 inhibitors, with the former approved only for relapsed/refractory AML and the latter approved o
IonQ Partners with Sweden’s Einride to Develop Quantum Supply Chain and Quantum-Enhanced Logistics for Autonomous Driving Solutions20.5.2025 23:05:00 EEST | Press release
IonQ (NYSE: IONQ), a leading commercial quantum computing and networking company, today announced an investment partnership with Einride, a leading global freight mobility company that provides digital, electric, and autonomous technology to explore how quantum computing can drive the next generation of fleet optimization and logistics. Together, IonQ and Einride will develop quantum applications that address large-scale routing and scheduling problems that have traditionally challenged classical computing. By combining IonQ’s advanced quantum systems with Einride’s expertise in autonomous fleet logistics, the two companies will work to unlock new levels of efficiency, reliability, and sustainability for the global freight industry. “Einride shares our belief that quantum computing will fundamentally reshape and improve how large industries such as transportation and logistics operate,” said Niccolo de Masi, CEO of IonQ. “This partnership is aimed at creating a powerful platform with u
CCM Biosciences Announces Presentation of Data on its First-In-Class NSCLC Drug Program at ASCO 202520.5.2025 22:26:00 EEST | Press release
CCM Biosciences, a diversified pharmaceutical discovery and development company, today announced the upcoming presentation of its 4th-generation EGFR inhibitor drug program for non-small cell lung cancer (NSCLC) at the 2025 Annual Conference of the American Society of Clinical Oncology (ASCO), taking place May 30 to June 3 in Chicago. NSCLC, which accounts for 80% of lung cancer, is the most common cause of cancer death worldwide. Epidermal growth factor receptor (EGFR)-activating mutations (Del19 or L858R) are major oncogenic drivers of NSCLC. EGFR-positive NSCLC accounts for approximately 30% of all diagnosed cases of NSCLC (a similar market size to PD-L1-positive NSCLC, which is addressed by the world’s top-selling drug, Keytruda®). The current standard of care for EGFR-positive NSCLC is comprised of 3rd-generation inhibitors, most notably Osimertinib (Tagrisso®), whose annual sales exceed $6 billion. Most patients treated by tyrosine kinase inhibitors (TKIs) will eventually develop
NielsenIQ's Chief Technology Officer Mohit Kapoor Named Executive of the Year at Global Tech & AI Awards for Leading NIQ’s AI-Driven Tech Transformation20.5.2025 22:24:00 EEST | Press release
NielsenIQ (NIQ) is proud to announce that Mohit Kapoor, Chief Technology Officer, was named Executive of the Year at the inaugural Global Tech & AI Awards. This honor recognizes Mohit's exceptional leadership and visionary contributions to the tech industry, particularly in the realm of AI-powered consumer intelligence. "I am deeply honored to receive the Executive of the Year award at the Global Tech & AI Awards. This recognition is a testament to the incredible work and dedication of the entire NielsenIQ team,” said Mohit Kapoor, Chief Technology Officer, NIQ. “Together, we have redefined consumer and retail intelligence, leveraging AI to deliver unparalleled insights and drive meaningful change in the industry." Under Mohit's leadership, NIQ has adopted an AI-powered approach to its ambitious digital transformation which included a $400 million technology investment and the migration of its global client base onto Discover– a unified, cloud-based platform that seamlessly integrates
Strategic Partnership Between the Government of Morocco and TAQA Morocco, Nareva, ONEE and the Mohammed VI Investment Fund to Develop Key Power and Water Infrastructures in the Kingdom of Morocco20.5.2025 22:08:00 EEST | Press release
As part of the implementation of the commitments made in the joint declaration between His Majesty King Mohammed VI, may God Assist Him, and His Highness Sheikh Mohamed bin Zayed Al Nahyan, TAQA Morocco, in partnership with Nareva and the Mohammed VI Fund for Investment, has signed three memorandums of understanding and related development agreements with the Government of Morocco and ONEE. These agreements cover the development of structuring projects in the power, water and renewable energy sectors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250520313620/en/ Strategic Partnership Between the Government of Morocco and TAQA Morocco, Nareva, ONEE and the Mohammed VI Investment Fund to Develop Key Power and Water Infrastructures in the Kingdom of Morocco (Photo: AETOSWire) The program aims to strengthen the Kingdom's water and energy sovereignty through the development of flexible natural gas-based power generation capacit
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom